Since then, shortages have ended, and the FDA says [archived link] the non-approved compounded versions can no longer be made and sold
These are the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon
In the push for coverage, the Director of the Department of Health and Human Services (DHHS) expressed that the drugs are phenomenal and that I believe that theyre being held back from the people of North Carolinawhen they could be promoting a great deal of value here in the buckle of the Barbecue Belt. The director also explained to lawmakers that it will not cost the state more than $10 million annually because the federal government will pay for most of it
Weve been hearing from employers, with increased alarm, about the cost of these medicines, said Blue Cross spokeswoman Amy McHugh
Marx N, Burgmaier M, Heinz P, Ostertag M, Hausauer A, Bach H, et al